Helix Biopharma Corp. Enters Into Asset Purchase Agreement to Acquire Oral Immune Checkpoint Inhibitor
LR 09 is a novel, patented chemical entity with Orphan Drug Designation from the US Food and Drug Administration (FDA) Helix Biopharma Corp. (TSX:HBP) TORONTO, ONTARIO, CANADA, November 29, 2024 /EINPresswire.com/ -- Helix BioPharma Corp. (TSX: …